|
Patient code
|
Patient isolates
|
Sex
|
Age
|
Risk factor
|
Time from first episode (in months)
|
Clinical status
|
Sample Type
|
WHO Code
|
Genotype (G)
|
Cluster (C)
|
|---|
|
P1
|
1a
|
Man
|
30
|
IVDU
|
June
|
CE
|
PBMC
|
MHOM/ES/00/BCN-278
|
G14
|
C2b
|
|
1b
| | | |
8 m
|
CE
|
PBMC
|
MHOM/ES/01/BCN-376
|
G13
|
C2b
|
|
1c
| | | |
20 m
|
CE
|
PBMC
|
MHOM/ES/02/BCN-464
|
G15
|
C2b
|
|
P2
|
2a
|
Man
|
44
|
IVDU
|
July
|
CE
|
BM
|
MHOM/ES/00/BCN-284
|
G3
|
C1
|
|
2b
| | | |
2 m
|
CE
|
BM
|
MHOM/ES/00/BCN-289
|
G2
|
C1
|
|
P3
|
3a
|
Man
|
36
|
nd
|
May
|
CE
|
BM
|
MHOM/ES/01/BCN-404
|
G16
|
C2
|
|
3b
| | | |
7 m
|
NE
|
PBMC
|
MHOM/ES/01/BCN-455
|
G16
|
C2
|
|
3c
| | | |
12 m
|
CE
|
BM
|
MHOM/ES/02/BCN-492
|
G16
|
C2
|
|
P4
|
4a
|
Man
|
34
|
IVDU
|
April
|
CE
|
BM
|
MHOM/ES/02/BCN-475
|
G9
|
C2
|
|
4b
| | | |
6 m
|
CE
|
BM
|
MHOM/ES/02/BCN-508
|
G9
|
C2
|
|
P5
|
5a
|
Man
|
36
|
IVDU
|
September
|
CE
|
BM
|
MHOM/ES/94/BCN-123
|
G10
|
C2
|
|
5b
| | | |
5 m
|
CE
|
BM
|
MHOM/ES/95/BCN-130
|
G1
|
-
|
|
P6
|
6a
|
Man
|
33
|
IVDU
|
October
|
CE
|
BM
|
MHOM/ES/00/BCN-298
|
G11
|
C2
|
|
6b
| | | |
6 m
|
CE
|
BM
|
MHOM/ES/01/BCN-400
|
G5
|
C2
|
|
6c
| | | |
17 m
|
CE
|
BM
|
MHOM/ES/02/BCN-470
|
G12
|
C2
|
|
P7
|
7a
|
Man
|
41
|
nd
|
October
|
CE
|
PBMC
|
MHOM/ES/01/BCN-430
|
G7
|
C2a
|
|
7b
| | | |
3 m
|
NE
|
BM
|
MHOM/ES/02/BCN-460
|
G7
|
C2a
|
|
7c
| | | |
4 m
|
CE
|
PBMC
|
MHOM/ES/02/BCN-472
|
G6
|
C2a
|
|
P8
|
8a
|
Woman
|
27
|
IVDU
|
October
|
CE
|
PBMC
|
MHOM/ES/00/BCN-293
|
G4
|
C2
|
|
8b
| | | |
1 m
|
NE
|
PBMC
|
MHOM/ES/00/BCN-306
|
G7
|
C2a
|
|
8c
| | | |
1 m + 6 days
|
NE
|
PBMC
|
MHOM/ES/01/BCN-307
|
G8
|
C2
|
|
8d
| | | |
3 m
|
NE
|
PBMC
|
MHOM/ES/01/BCN-369
|
G16
|
C2
|
|
8e
| | | |
7 m
|
CE
|
PBMC
|
MHOM/ES/01/BCN-405
|
G18
|
C2
|
|
8f
| | | |
9 m
|
NE
|
PBMC
|
MHOM/ES/01/BCN-422
|
G17
|
C2
|
|
8 g
| | | |
29 m
|
NE
|
PBMC
|
MHOM/ES/03/BCN-561
|
G16
|
C2
|
-
IVDU intravenous drug user, nd not determined, CE clinical episode, NE non-clinical episode, PBMC peripheral blood mononuclear cell, BM bone marrow
